Call Us Free: (800) 385-2536

FDA advisory panel recommends approval of Spark Therapeutics' gene therapy

A Food and Drug Administration advisory committee voted Thursday to recommend approval of Spark Therapeutics’ application for its experimental gene therapy developed to treat vision loss caused by an inherited retinal disease.

The vote by the Cellular, Tissue and Gene Therapies Advisory Committee was unanimous.

Spark’s stock price was up about 2 percent at $86.20 per share in after-hours trading shortly after the committee’s vote was announced.

The company, which was spun out of Children’s…

Source link

Leave a Reply